Paul Kim, MD
Radiation Oncology · Tustin, CANPI 1629205190
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,025 of the $15,010 with a category attached, or 93.4%. Palette Life Sciences, Inc. accounts for 94.4% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2023 at $8,853 and has fallen 97.7% since, to $206 in 2025. Among radiation oncology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 42 payments — averaging $357.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Palette Life Sciences, Inc.$14K
- Blue Earth Diagnostics$155
- Myovant Sciences Inc.$93
- Dendreon Pharmaceuticals LLC$91
- Teleflex LLC$83
- Hologic Sales And Service, LLC$58
- plus $364 from 14 others
What the payments were for
- Consulting fees$14,02593%
- Food & beverage$9616%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Palette Life Sciences, Inc. | 8 | $14,167 |
| Blue Earth Diagnostics | 6 | $155 |
| Myovant Sciences Inc. | 4 | $93 |
| Dendreon Pharmaceuticals LLC | 3 | $91 |
| Teleflex LLC | 3 | $83 |
| Hologic Sales And Service, LLC | 1 | $58 |
| Johnson & Johnson | 3 | $53 |
| Novartis | 2 | $51 |
| Bayer | 1 | $29 |
| Visionrt, Inc. | 1 | $28 |
| Bioprotect Medical, Inc. | 1 | $26 |
| Astellas Pharma US Inc | 1 | $25 |
| Tolmar Pharmaceuticals, Inc. | 1 | $25 |
| Pfizer | 1 | $24 |
| Novocure Inc. | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Myriad Genetic Laboratories, Inc. | 1 | $18 |
| Telix Pharmaceuticals | 1 | $18 |
| Varian Medical Systems, Inc. | 1 | $18 |
| Merck | 1 | $12 |
How this compares
$15,010 in reported general payments places this provider in the 90th percentile of 627 radiation oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 16 | $42,827 |
| Abiraterone Acetate | 34 | $42,577 |
| Tadalafil | 15 | $3,499 |
| Tamsulosin Hcl | 166 | $2,286 |
| Solifenacin Succinate | 21 | $880 |
| Oxybutynin Chloride ErOxybutynin Chloride | 47 | $654 |
| Bicalutamide | 24 | $333 |
| Ciprofloxacin Hcl | 76 | $234 |
| Dexamethasone | 11 | $114 |
| Medroxyprogesterone Acetate | 17 | $99 |
| Prednisone | 26 | $98 |
| Tramadol Hcl | 16 | $73 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Tustin
- Rakesh PatelLos Gatos$1.3M
- Amir LavafPalm Springs$411K
- Albert ChangLos Angeles$290K
- Arya AminiDuarte$265K
- Rizwan NuraniApple Valley$220K
- Drew MoghanakiLos Angeles$183K
- Jyoti MayadevSan Diego$170K
- Percy LeeIrvine$125K
- Felix FengSan Francisco$99K
- Hyun KimDuarte$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.